Cart (0 Items)
Your cart is currently empty.
View ProductsStable Isotope Labelled Satralizumab Biosimilar – Anti-IL6R mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Isotope Labelled Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade |
|---|---|
| Source | CAS 1535963-91-7 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | MS |
| Aliases /Synonyms | SA-237 |
| Reference | PX-TA1407-SIL |
| Related Products | PX-P4046 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG2-kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
Description of Stable Isotope Labelled Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade
General information on Anti-IL6R[Homo sapiens] (Satralizumab) Monoclonal Antibody
Satralizumab is a humanized monoclonal antibody that targets human interleukin-6 (IL-6) receptors, similar to tocilizumab. Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD). Increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier are thought to be mediated by IL-6. Satralizumab is thought to block IL-6 receptors and, thereby, these inflammatory responses.
Reviews
Il n’y a pas encore d’avis.